Medical/Pharmaceuticals

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096)  announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute ofMateria Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinica...

2022-05-18 11:56 3047

Sinclair Pharma Partners with Vanguard Aesthetics to Launch Silhouette Soft in Malaysia

Equipped with the world's only cone technology for optimal lift, Silhouette Soft provides longer lasting results. KUALA LUMPUR, Malaysia, May 18, 2022 /PRNewswire/ -- Sinclair Pharma , a global pharmaceutical brand providing aesthetic dermatology and collagen solutions is ...

2022-05-18 09:01 5044

Vela Diagnostics Launches Multiplex PCR-Based Test for Detecting UTI Pathogens and Antimicrobial Resistance Genes

FAIRFIELD, N.J., 17 May, 2022  /PRNewswire/ -- Vela Diagnostics announced today the launch of its new PathoKey® MP UTI ID and AMR PCR Test for research use only (RUO*). This multiplex PCR-based test allows for the in vitro detection and differentiation of 14 pathogens that cause urinary tract in...

2022-05-17 22:00 3035

KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood ...

2022-05-17 20:00 2650

P&G Health dons the Purple Ribbon to commemorate Neuropathy Awareness Week

* Launches 'Feel Life' campaign in 18 countries across Asia Pacific, Middle East, India, and Africa to raise awareness on Peripheral Neuropathy * Global Webinar Series for healthcare professionals with 'Virtual Pavilions' representing Peripheral neuropathy issues in each country, along with be...

2022-05-17 19:24 3404

ASEAN accepts mutually recognized COVID-19 vaccination certificates

DENPASAR, Indonesia, May 17, 2022 /PRNewswire/ -- ASEAN Member States collectively recognize the COVID-19 vaccination certificate to be applied in Southeast Asia. Health Ministers of ASEAN countries endorsed the decision during the 15th ASEAN Health Ministers Meeting (15th AHMM) inNusa Dua, Bali, ...

2022-05-17 19:14 3196

New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore

* Over the course of the VICTORIA study, there was a 4.2% reduction in annualized absolute risk with VERQUVO™ (vericiguat) compared with placebo in reducing the risk of cardiovascular death or heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less th...

2022-05-17 16:32 2449

ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY

PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL ), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma Therapeutics (Od...

2022-05-17 15:00 4474

CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis

* Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent or sequential chemoradiotherapy * The National Medical Pr...

2022-05-17 08:02 4334

LifeOmic Applauded by Frost & Sullivan for Enabling More Cost-efficient, Targeted Holistic Precision Health with Its Interoperable Precision Health Solutions

The Interoperable Precision Health Solutions improve access, flexibility, agility, and awareness, driving adoption anddelivering more cost-efficient, targeted healthcare utilization. SAN ANTONIO, May 16, 2022 /PRNewswire/ -- Based on a recent industry assessment of the precision health informati...

2022-05-16 22:00 3055

Ascletis (1672.HK) Included in MSCI China Small Cap Index

HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the MSCI China Small Cap Index, effective after the market close onMay 31, 2022. Morgan Stanley Capital International (MSCI) is a leading provider o...

2022-05-16 20:17 5884

SOFWAVE™ TECHNOLOGY WINS MAJOR BEAUTY AWARDS -- 2022 ADDING TO THE 2021 ELLE AWARD

Cosmopolitan, NewBeauty, and SHAPE Name Sofwave™ Technology the Industry's Best SAN CLEMENTE, Calif., May 16, 2022 /PRNewswire/ -- Sofwave™ Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, is thrilled to announce it ...

2022-05-16 20:00 3419

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

-Distribution channels in place to streamline/facilitate patient access. -XPOVIO® will be available in 600 hospitals and 105 DTPs (across China includingBeijing, Shanghai, Guangdong, Jiangsu, Zhejiang, Henan, and Shandong). SHANGHAI and HONG KONG, May 16, 2022 /PRNewswire/ -- Antengene Corporatio...

2022-05-16 11:20 4315

Pocared Diagnostics, an Israeli rapid infectious diseases diagnostics leader, secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system

- First EIB support for medtech investment in Israel - Financing to accelerate development of rapid testing system to improve infectious disease diagnosis and antibiotics stewardship - Automated phenotypic testing, revolutionizing infectious diseases diagnostics from sample to answer REHOVOT, I...

2022-05-16 10:00 4122

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

SUZHOU, China, May 15, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter referred to as "GeneQuantum"), a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won...

2022-05-16 09:00 3101

UMP Purchases Advanced Medical Imaging Equipment and Facilities

Further Extends its Services Area in Central CBD with New Centre Opening HONG KONG, May 16, 2022 /PRNewswire/ -- UMP Healthcare Holdings Limited ("UMP" or the "Group", SEHK: 722) is pleased to announce that it will rent the whole of 1st floor, 2nd floor, 3rd floor (plus a terrace) and 5th floor o...

2022-05-16 08:00 4314

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-05-16 08:00 4819

Kintor Pharma Included in MSCI China Index

SUZHOU, China, May 15, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced today that the company's stock has been included in the MSCI China Index, e...

2022-05-15 18:28 4467

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma (r/r PTCL) in oral session at the 27th European Hematology Association 2022 (EHA2022)...

2022-05-13 19:09 3528

Seegene reports first quarter 2022 financial results

* Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion * Foundation for sales expansion strengthened through '3 Ct' technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales * "Seegene to secure future growth by targeting syndromic t...

2022-05-13 19:00 3533
1 ... 569570571572573574575 ... 643